



# ASX Release

## Cleansing Notice under Section 708A of the Corporations Act 2001 (Cth)

**Melbourne, Australia – 20 January 2026:** Adherium Limited (ASX: ADR) (the Company) gives notice under section 708A(5)(e) of the Corporations Act 2001 (Corporations Act) regarding the 25,510,000 fully paid ordinary shares (Shares) as detailed in Appendix 2A dated 20 January 2026.

For the purposes of sections 708A(5)(e)(i) and 708A(6) of the Corporations Act 2001 (Cth) (Corporations Act), the Company advises:

- (a) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
- (b) this notice is being given under section 708A(5)(e) of the Corporations Act;
- (c) as at the date of this notice, the Company has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (ii) sections 674 and 674A of the Corporations Act; and
- (d) as at the date of this notice, there is no information that is 'excluded information' (within the meaning of sections 708A(7) and 708A(8) of the Corporations Act) that is required to be disclosed.

**For more information about Adherium and its revolutionary respiratory solutions, please visit [adherium.com](http://adherium.com).**

**- ENDS -**

This ASX announcement was approved and authorised for release by the Board of Adherium.

### Investor Enquiries

[investors@adherium.com](mailto:investors@adherium.com)

### Media Enquiries:

Haley Chartres  
H^CK  
Director  
[haley@hck.digital](mailto:haley@hck.digital)

### About Adherium (ASX: ADR)



## ASX Release

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices. Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management.

The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease.

Learn more at [adherium.com](http://adherium.com)